You are here

Article Text

Article menu

other Versions

Download PDFPDF
Miscellaneous
Journal club
Lebrikizumab may benefit a subset of patients with asthma
  1. Sasiharan Sithamparanathan
  1. Correspondence to Dr Sasiharan Sithamparanathan, ST3, King George Hospital, Barley Lane, Goodmayes, Essex IG3 8YB, UK; sasiharan_9{at}hotmail.com

https://doi.org/10.1136/thoraxjnl-2011-201329

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Interleukin 13 (IL-13), a cytokine of type 2 helper T cells, may contribute to the heterogeneity of asthma in terms of clinical course and response to treatment. IL-13 leads to the production of periostin, a protein that may cause airway remodelling.

    In this randomised, double-blind, placebo-controlled study, lebrikizumab, a monoclonal antibody that binds to IL-13 thereby inhibiting …

    View Full Text

    Footnotes

    • Provenance and peer review Not commissioned; internally peer reviewed.